Los Angeles, CANCT06459869Now EnrollingIRB Ready

Locally Advanced Rectal Cancer (LARC) Clinical Trial in Los Angeles, CA

Access cutting-edge locally advanced rectal cancer (larc) treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Akamis Bio

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access locally advanced rectal cancer (larc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related locally advanced rectal cancer (larc) treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this locally advanced rectal cancer (larc) clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Locally Advanced Rectal Cancer (LARC) Study in Los Angeles

The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.

Sponsor: Akamis Bio

Who Can Participate

Inclusion Criteria

Histologically confirmed adenocarcinoma of the rectum.
Locally advanced disease (clinical stage II-III based on pelvic MRI) selected by a multidisciplinary team for treatment with neoadjuvant CRT (which may be followed by CNCT to comprise planned TNT). Patients with oligometastatic disease are permitted provided that the site-specific multidisciplinary team deems them suitable for radical treatment/chemoradiation.
Confirmed microsatellite stable (MSS)/proficient mismatch repair (pMMR) status.
Provide written informed consent to participate.
ECOG Performance Status 0 or 1.
Must not be pregnant or breastfeeding.
Patients who are sexually active (with either sex) must agree to comply with contraceptive requirements.
Adequate lung reserve, renal function, hepatic function, and bone marrow/hematological function assessed ≤ 10 days prior to first dose. Selected

Exclusion Criteria

Recurrent rectal cancer.
Distant metastatic disease not amenable to radical treatment/chemoradiation.
Other prior malignancy active within the previous 3 years, except for local or organ confined early-stage cancer that has been definitively treated with curative intent, does not require ongoing treatment, has no evidence of residual disease, and has a negligible risk of recurrence and is therefore unlikely to interfere with the primary and secondary endpoints of the trial, including response rate and safety.
Splenectomy (patients with prior partial resection remain eligible if the Investigator considers splenic function to not be significantly compromised).
Active autoimmune disease that has required systemic therapy in the past 2 years, immunocompromised status in the opinion of the Investigator, or current treatment with systemic immunosuppressive therapy (daily prednisone equivalent for chronic system replacement not to exceed 10mg per day).
Infectious or inflammatory bowel disease in the 3 months before the first dose of study treatment.
Any clinically significant cardiovascular, peripheral vascular, cerebrovascular, or thromboembolic event in the last 1 month before the first dose of study treatment.
Major surgery in the 14 days before the first dose of study treatment or any surgical wounds that are not fully healed and free of infection or dehiscence.
Any prior surgery for rectal cancer or pelvic radiotherapy.
Any other anti-cancer or experimental therapy within the previous 12 months or that is planned during the active study treatment period.
Treatment with any other enadenotucirev-based virus (parent virus or transgene-modified variants), or anti-CD40 antibody at any time.
History of prior Grade 3-4 acute kidney injury or other clinically significant renal impairment.
Any ongoing Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 coagulation abnormality/coagulopathy. URL: https://www.FortressStudy.org

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT06459869) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Locally Advanced Rectal Cancer (LARC) Treatment Options in Los Angeles, CA

If you're searching for locally advanced rectal cancer (larc) treatment options in Los Angeles, CA, this clinical trial (NCT06459869) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced locally advanced rectal cancer (larc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all locally advanced rectal cancer (larc) clinical trials near you to find additional studies recruiting in your area.

More Colorectal Cancer Trials in Los Angeles, CA

See all colorectal cancer clinical trials recruiting in Los Angeles — not just this study.

Browse Colorectal Cancer Trials in Los Angeles →

Browse More Trials by Condition

Colorectal Cancer TrialsLeukemia TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA